enzastaurin has been researched along with Breast Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Alaoui-Jamali, MA; Amzil, H; Bijian, K; Lim, FPL; Miron, CE; Moitessier, N; Nivedha, AK; Su, J; Wernic, D | 1 |
| Bhatt, AN; Katiyar, A; Misra, G; Polisety, A; Rajawat, J; Singh, H | 1 |
| Hristova-Kazmierski, M; Isakoff, SJ; Johnson, C; Krop, I; Miller, KD; Mina, L; Schneider, CJ; Shonukan, OO; Sledge, GW; Vaughn, LG; Wang, Y; Yu, M; Zon, RT | 1 |
| Abdulnabi, R; Clemons, M; Gelmon, K; Iscoe, N; Jordaan, JP; Joy, AA; Kotliar, M; Lynch, J | 1 |
| Gökmen-Polar, Y; Sledge, GW | 1 |
| Dudek, AZ; Jasinski, P; Terai, K; Zwolak, P | 1 |
1 review(s) available for enzastaurin and Breast Cancer
| Article | Year |
|---|---|
Protein kinase C-beta as a therapeutic target in breast cancer.
Topics: Breast Neoplasms; Enzyme Inhibitors; Female; Humans; Indoles; Neovascularization, Pathologic; Protein Kinase C; Protein Kinase C beta; Vascular Endothelial Growth Factor A | 2006 |
2 trial(s) available for enzastaurin and Breast Cancer
| Article | Year |
|---|---|
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Female; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2009 |
Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Argentina; Australia; Breast Neoplasms; Canada; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Mexico; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Placebo Effect; Proportional Hazards Models; Risk Assessment; Risk Factors; South Africa; Taxoids; Time Factors; Treatment Outcome | 2010 |
3 other study(ies) available for enzastaurin and Breast Cancer
| Article | Year |
|---|---|
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
Topics: Antineoplastic Agents; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Hydrogen Bonding; Isoenzymes; Molecular Docking Simulation; Protein Kinase C; Protein Kinase Inhibitors; Selenium Compounds; Small Molecule Libraries; Structure-Activity Relationship; Substrate Specificity; Tumor Stem Cell Assay | 2022 |
Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indoles; Microtubule-Associated Proteins; Piperazines; Protein Serine-Threonine Kinases; Pyridines | 2022 |
Enzastaurin renders MCF-7 breast cancer cells sensitive to radiation through reversal of radiation-induced activation of protein kinase C.
Topics: Annexin A5; Apoptosis; Blotting, Western; Breast Neoplasms; Caspase 3; Caspase 9; Cell Survival; Cytosol; Dactinomycin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gamma Rays; Humans; Indoles; Phosphorylation; Protein Kinase C; Radiation-Sensitizing Agents; Repressor Proteins; Tumor Cells, Cultured | 2008 |